Dr. Herbst on Immunotherapy in Lung Cancer

Video

In Partnership With:

Roy S. Herbst, MD, PhD, chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses immunotherapy for patients with lung cancer.

Roy S. Herbst, MD, PhD, professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses immunotherapy for patients with lung cancer.

While researchers and physicians are constantly identifying mutations in tumors, realistically, 70% or more of patients may not have an actionable mutation for which they can receive an oral targeted agent. Many of these patients, Herbst says, are benefiting from an antibody against PD-1 or PD-L1, important regulators of the immune checkpoint.

Many tumors are immunogenic and can be killed by T cells. These tumors, however, express a protein (PD-L1) that acts as a cloaking device by keeping the tumor invisible to the immune system. Herbst notes that it is becoming increasingly possible to interact and break up that invisibility, using immunotherapies.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD